Psoriasis and smoking: links and risks published by Dove Medical Press
Psoriasis: Targets and Therapy has published the review “Psoriasis and smoking: links and risks”.
Smoking impacts on the clinical severity of psoriasis, its response to treatment and explains some of the associated co-morbidities, e.g., cardiovascular disease, inflammatory bowel disease, and several cancers (especially those of the respiratory tract).
As corresponding author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy throws new light on the relation between smoking habits and psoriasis. Smoking influences the onset and the severity of psoriasis, and negatively influences the response to systemic treatment. Several pathomechanisms are involved including oxidative stress, interaction with signalling pathways and vascular influences. Dermatologists could play a major role in reducing the health burden of smoking by influencing their patients changing behavior.”
As Dr Uwe Wollina, Editor-in-Chief, explains “This paper demonstrates important links between smoking and worsening of psoriasis or reduced therapeutic response of the disease. It points to the fact that patients who are a smoker and are affected by psoriasis can positively influence the course of their disease by quitting smoking.”
Psoriasis: Targets and Therapy is an international, peer-reviewed, open access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis and related conditions, identification of therapeutic targets and the optimal use of integrated treatment interventions to achieve improved outcomes and quality of life.
Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine.
Updated 31 May 2016